All posts

Follow Us

LinkedInInstagramX
Quarterly ResultsArchiveLast updated 11 November 20263 min read

Oxygenta Pharmaceutical (OXYGENTAPH) Q2 FY27's Revenue Jumps 135% but Losses Deepen Sequentially

The pharma firm's Q2 FY27 sales more than doubled year-on-year, but a sharp rise in interest and material costs pushed its net loss wider from the previous quarter.

By Anant Kacholia, HexaWealth Research · Created 11 November 2026

Oxygenta Pharmaceutical's September quarter revenue surged 135% year-on-year to ₹33.49 crore. However, its net loss widened sequentially to ₹2.73 crore as interest costs nearly tripled and material expenses rose sharply.

For Oxygenta Pharmaceutical, the September quarter presented a stark divergence. The company achieved a massive scale-up, with revenue more than doubling from a low base. Yet, this growth came at a steep cost, as the path to profitability remains blocked by rising financial and operational expenses.

The numbers tell a story of two opposing forces. Revenue jumped 135% year-on-year to ₹33.49 crore, a significant improvement from ₹14.25 crore in Q2 FY26. Sequentially, however, sales dipped 9.5% from ₹37.0 crore in the June quarter. The net loss of ₹2.73 crore was 44.6% narrower than the year-ago loss of ₹4.93 crore, but it widened by 30% from the ₹2.1 crore loss in Q1 FY27.

Revenue & profit

Revenue (₹ Cr)

Profit (₹ Cr)

Revenue & profitQ2 FY26 (Sep 2025) 14.25, Q3 FY26 (Dec 2025) 33.93, Q4 FY26 (Mar 2026) 49.61, Q1 FY27 (Jun 2026) 37.00, Q2 FY27 (Sep 2026) 33.49. Q2 FY26 (Sep 2025) -4.93, Q3 FY26 (Dec 2025) -4.84, Q4 FY26 (Mar 2026) -1.70, Q1 FY27 (Jun 2026) -2.10, Q2 FY27 (Sep 2026) -2.73-80-4004080Q2 '26Q3 '26Q4 '26Q1 '27Q2 '27
  • Revenue (₹ Cr), Q2 FY26 (Sep 2025): 14.25
  • Revenue (₹ Cr), Q3 FY26 (Dec 2025): 33.93
  • Revenue (₹ Cr), Q4 FY26 (Mar 2026): 49.61
  • Revenue (₹ Cr), Q1 FY27 (Jun 2026): 37.00
  • Revenue (₹ Cr), Q2 FY27 (Sep 2026): 33.49
  • Profit (₹ Cr), Q2 FY26 (Sep 2025): -4.93
  • Profit (₹ Cr), Q3 FY26 (Dec 2025): -4.84
  • Profit (₹ Cr), Q4 FY26 (Mar 2026): -1.70
  • Profit (₹ Cr), Q1 FY27 (Jun 2026): -2.10
  • Profit (₹ Cr), Q2 FY27 (Sep 2026): -2.73

Revenue (₹ Cr)

Revenue (₹ Cr)Q2 FY26 (Sep 2025) 14.25, Q3 FY26 (Dec 2025) 33.93, Q4 FY26 (Mar 2026) 49.61, Q1 FY27 (Jun 2026) 37.00, Q2 FY27 (Sep 2026) 33.49020406080Q2 '26Q3 '26Q4 '26Q1 '27Q2 '27
  • Revenue (₹ Cr), Q2 FY26 (Sep 2025): 14.25
  • Revenue (₹ Cr), Q3 FY26 (Dec 2025): 33.93
  • Revenue (₹ Cr), Q4 FY26 (Mar 2026): 49.61
  • Revenue (₹ Cr), Q1 FY27 (Jun 2026): 37.00
  • Revenue (₹ Cr), Q2 FY27 (Sep 2026): 33.49

Profit (₹ Cr)

Profit (₹ Cr)Q2 FY26 (Sep 2025) -4.93, Q3 FY26 (Dec 2025) -4.84, Q4 FY26 (Mar 2026) -1.70, Q1 FY27 (Jun 2026) -2.10, Q2 FY27 (Sep 2026) -2.73-8-4048Q2 '26Q3 '26Q4 '26Q1 '27Q2 '27
  • Profit (₹ Cr), Q2 FY26 (Sep 2025): -4.93
  • Profit (₹ Cr), Q3 FY26 (Dec 2025): -4.84
  • Profit (₹ Cr), Q4 FY26 (Mar 2026): -1.70
  • Profit (₹ Cr), Q1 FY27 (Jun 2026): -2.10
  • Profit (₹ Cr), Q2 FY27 (Sep 2026): -2.73
MetricCurrentQ2 FY27 (Sep 2026)PreviousQ1 FY27 (Jun 2026)
Revenue (₹ Cr)
33.49
37.00
Profit (₹ Cr)
-2.73
-2.10
PAT Margin (%)
-8.2
-5.7

The Cost of Growth

The revenue surge did not translate to the bottom line due to a severe margin squeeze. A report from ScanX.trade notes that the cost of materials consumed was approximately 73% of operating revenue. This, coupled with a near-tripling of finance costs to ₹2.73 crore, eroded any potential operating profit.

The spike in interest expense, up 187% year-on-year, points to higher borrowings funding working capital needs. FlashFinance data shows borrowings rose to ₹283 crore as of September 2026, up from ₹264 crore in March. This growing debt burden is a direct drag on earnings.

A Glimmer in Operations

Despite the net loss, there was a notable operational improvement. The company reported a near-break-even operating profit of ₹0.03 crore, a dramatic recovery from an operating loss of ₹4.57 crore a year ago. This suggests the core manufacturing business is scaling, but profitability is being swallowed by financing costs.

Live Chart

· OXYGENTAPH

(BSE)

ISIN: INE102E01018

Management commentary, as reported by StockWatch, was limited to announcing the results. The board did approve a strategic land acquisition in Telangana for ₹6.75 crore to support future expansion, indicating a focus on long-term infrastructure.

Key Points

  • Revenue more than doubled year-on-year but declined sequentially from the previous quarter.
  • The net loss widened quarter-on-quarter as soaring interest and material costs offset top-line growth.
  • Operating performance improved significantly, moving close to breakeven from a deep loss a year ago.
  • Borrowings increased, leading to a near-tripling of finance costs which continues to pressure the bottom line.

Hexa Perspective

The quarter underscores a company caught between scaling operations and a strained balance sheet. The operational turnaround from last year's deep losses is evident, showing the business can generate revenue. However, the sustainability of this model is in question.

Profitability hinges on two factors: stabilizing revenue at these higher levels to absorb fixed costs, and managing the cost of capital. Until the company demonstrates an ability to generate consistent operating profits that can cover its financing expenses, the net loss trend is likely to persist. Investors are left weighing the operational progress against the financial leverage that currently funds it.

Share or follow HexaWealth

Also read

Want this applied to your portfolio?

Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.

Oxygenta Pharmaceutical (OXYGENTAPH) Q2 FY27 results, revenue and profits.

Frequently asked questions

What were Oxygenta Pharmaceutical's Q2 FY27 results?
Oxygenta Pharmaceutical reported Q2 FY27 revenue of ₹33.49 crore, a 135% increase year-on-year. The company's net loss was ₹2.73 crore, which was 44.6% narrower than the loss in Q2 FY26 but 30% wider than the loss in the preceding Q1 FY27.
Why did Oxygenta Pharmaceutical's Q2 profit drop sequentially despite higher sales?
Oxygenta's net loss widened quarter-on-quarter in Q2 FY27 primarily due to a sharp rise in interest costs, which nearly tripled year-on-year to ₹2.73 crore. High input costs, with materials consuming about 73% of revenue per ScanX.trade, also pressured margins despite the sales growth.
What was Oxygenta Pharmaceutical's net profit margin in Q2 FY27?
Oxygenta Pharmaceutical's net profit margin was -8.2% in Q2 FY27. This marks a significant 2,640 basis point improvement from -34.6% in Q2 FY26, but a 250 basis point deterioration from -5.7% in Q1 FY27.
Why did Oxygenta Pharmaceutical's interest expense surge 187% in Q2 FY27?
Oxygenta Pharmaceutical's interest expense surged due to increased borrowings to fund working capital needs for its expanding operations. Data from FlashFinance indicates borrowings rose to ₹283 crore in September 2026 from ₹264 crore in March 2026.
What was Oxygenta Pharmaceutical's management outlook after Q2 FY27?
Management commentary was limited to announcing the unaudited results and a land acquisition for expansion. An analysis by Univest.in noted the full-year outlook depends on subsequent quarters, with no specific forward guidance provided in the filing.
What is the status of Oxygenta Pharmaceutical's debt and balance sheet?
Oxygenta Pharmaceutical's borrowings increased to ₹283 crore as of September 2026. While some reports highlight a low debt-to-assets ratio from FY26, the recent surge in borrowings and interest costs points to a rising debt burden funding current operations.
What are Oxygenta Pharmaceutical's expansion plans?
Oxygenta Pharmaceutical's board approved the acquisition of a plot of land in Telangana for ₹6.75 crore. As reported by StockWatch, this strategic move is aimed at supporting future business expansion and establishing additional infrastructure.
Did Oxygenta Pharmaceutical's Q2 FY27 results beat estimates?
There is no available consensus of analyst estimates for comparison. However, FlashFinance analysis shows the company's Q2 sales of ₹33.5 crore were significantly above its own historical trend, which was projected at ₹14.6 crore.
Oxygenta Pharmaceutical Q2 FY27 results August 2026
Oxygenta Pharmaceutical announced its Q2 FY27 (July-September 2026) results on November 10, 2026. For the quarter, the company reported revenue of ₹33.49 crore and a net loss of ₹2.73 crore.
Oxygenta Pharmaceutical Q2 net profit
Oxygenta Pharmaceutical's Q2 FY27 net profit was a loss of ₹2.73 crore. This compares to a net loss of ₹4.93 crore in Q2 FY26 and a net loss of ₹2.10 crore in Q1 FY27.